GLP-1s may increase risk of osteoporosis and gout, new research findsGLP-1s may increase risk of osteoporosis and gout, new research finds
GLP-1 drugs — including Ozempic and Wegovy — may be tied to a slightly higher risk of osteoporosis and gout, according to research presented Monday at the American Academy of Orthopaedic Surgeons’ annual meeting.Dr. GLP-1 drugs — including Ozempic and Wegovy — may be tied to a slightly higher risk of osteoporosis and gout, according Read More
Use of Complementary and Alternative Medicine in the Management of Breast CancerUse of Complementary and Alternative Medicine in the Management of Breast Cancer
This cohort study assesses the association of complementary and alternative medicine plus traditional therapies, including surgery, chemotherapy, radiation, endocrine therapy, and immunotherapy, with survival in female patients with breast cancer.
GLP-1 Drugs Tied to Unexpected Migraine BenefitsGLP-1 Drugs Tied to Unexpected Migraine Benefits
(MedPage Today) — Chronic migraine patients who used GLP-1 receptor agonists to treat conditions like obesity or diabetes had fewer emergency department (ED) visits than those on topiramate (Topamax), a real-world data analysis showed. Compared… (MedPage Today) — Chronic migraine patients who used GLP-1 receptor agonists to treat conditions like obesity or diabetes had Read More
Hidden ingredient in Ozempic and Wegovy tablets raises new gut health questionsHidden ingredient in Ozempic and Wegovy tablets raises new gut health questions
Scientists are taking a closer look at the pill forms of Wegovy and Ozempic. In an animal study, the ingredient SNAC, which helps semaglutide survive the stomach and enter the bloodstream, was associated with changes in gut bacteria, inflammation markers, and a brain linked protein. The research does not show harm in people, but it Read More
Understanding GLP-1 signaling: A path to better therapiesUnderstanding GLP-1 signaling: A path to better therapies
About one in eight U.S. adults are currently taking a GLP-1 drug such as Ozempic, Wegovy, or Zepbound to treat diabetes, obesity, or other conditions, according to a KFF Health Tracking poll. But many suffer from significant side effects including nausea or vomiting. And for diabetic patients who also have conditions such as cancer or Read More
Hypertension treatment linked to lower mortality for patients with metastatic breast cancerHypertension treatment linked to lower mortality for patients with metastatic breast cancer
Women with metastatic breast cancer often face multiple chronic conditions, and high blood pressure is among the most common. Nearly half of women in this study population had hypertension at diagnosis, with even higher rates among Black and Hispanic patients. Researchers have recently sought to understand whether more effective hypertension management could improve survival. Their work appears in Cancer Medicine.
There is more than one way for triple-negative breast cancer to become resistant to therapyThere is more than one way for triple-negative breast cancer to become resistant to therapy
About 50% of triple-negative breast cancer (TNBC) patients develop resistance to therapy. When resistance arises, tumors are more likely to come back after the original treatment, significantly reducing the chances of survival. Researchers at Baylor College of Medicine have discovered that there is more than one way TNBC can become immune to therapy.
Novel GLP-1 Pill Tops Oral Semaglutide for DiabetesNovel GLP-1 Pill Tops Oral Semaglutide for Diabetes
(MedPage Today) — An investigational GLP-1 receptor agonist pill edged out oral semaglutide (Rybelsus) for improving blood glucose in adults with type 2 diabetes inadequately controlled on metformin, the phase III ACHIEVE-3 trial showed. Among… (MedPage Today) — An investigational GLP-1 receptor agonist pill edged out oral semaglutide (Rybelsus) for improving blood glucose in Read More
Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetesOral semaglutide found to lower risk of heart failure events in people with type 2 diabetes
An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with type 2 diabetes who already had heart failure. The findings, published in JAMA Internal Medicine, come from a large randomized trial of nearly 9,650 adults who have Read More
A promising new drug for an invasive type of breast cancerA promising new drug for an invasive type of breast cancer
EPFL researchers have developed preclinical models for invasive lobular carcinoma and trialed a new drug. It slows tumor growth effectively by targeting specific features of the disease and opening the door to future clinical trials. The study is published in Cancer Research.